Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2− metastatic breast cancer patients compared to endocrine therapy alone in the second‐line setting: A large institutional study
Abstract
Cyclin‐dependent‐kinase‐4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) is standard of care for patients with advanced hormone receptor (HR)‐positive, HER2‐negative breast cancer (BC). The Breast Medical Oncology database at MD Anderson Cancer Center (MDACC) was analyzed to assess effectiveness of the CDK4/6i palbociclib plus ET compared to ET alone. From a total of 5402 advanced HR+ HER2− BC patients referred to MDACC between 1997 and 2020, we identified eligible patients who received palbociclib in combination with first‐line (n = 778) and second‐line (n = 410) ET. We further identified “control” patients who received ET alone in the first‐line (n = 2452) and second‐line (n = 1183) settings. Propensity score matching analysis was conducted to balance baseline demographic and clinical characteristics between palbociclib and control cohorts to assess the effect of palbociclib treatment on progression‐free survival (PFS) and overall survival (OS). For propensity‐matched‐cohort in the first‐line setting (n = 708), palbociclib group had significantly longer median PFS (17.4 vs 11.1 months; P P P < .022), compared to controls. We conclude that in this single center analysis of a large cohort of metastatic HR+ HER2− BC patients, palbociclib in combination with ET was associated with improved PFS in both first‐line and second‐line settings and OS in the second‐line setting compared to ET alone cohort.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 03, 2022
- Source ID
- 10.1002/ijc.33959
Entities
People
- Akshara Raghavendra
- Debu Tripathy
- Kelly K. Hunt
- Khandan Keyomarsi
- Min Jin Ha
- Nicole M Kettner
- Rachel M. Layman
- Senthil Damodaran
- Wei Qiao
- Yu Shen
Organizations
- Cancer Prevention and Research Institute of Texas
- National Cancer Institute
- United States Department of Defense
- University of Texas at Austin
- Yonsei University